glp 1 and liver enzymes Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty disease (NAFLD) non-alcoholic steatohepatitis (NASH) GLP-1 Receptor Agonists in Non-Alcoholic

Nature 578 , 444448 (2020)

Cardiovascular and renal outcome trials continue producing evidence that shapes guideline recommendations

Environmental (diet, exercise habit, endocrine-disrupting chemicals, etc.) and disease-specific factors likely contribute as well (133)

For example, in a 16-week, placebo-controlled trial of an age-advanced cohort receiving nightly subcutaneous GHRH analogue (a sermorelin-like peptide), treatment activated endogenous GH pulsatility and significantly increased integrated nocturnal GH levels

These typically occur during dose escalation and usually diminish as the body adjusts to treatment

The study by Teichman et al